October 22, 2014Open Access

Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

FOLFOXIRI plus bevacizumab, as compared with FOLFIRI plus bevacizumab, improved the outcome in patients with metastatic colorectal cancer and increased the incidence of some adverse events. (Funded by the Gruppo Oncologico Nord Ovest and others; ClinicalTrials.gov number, NCT00719797.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Fotios Loupakis

University of Pisa

Chiara Cremolini

University of Pisa

Gianluca Masi

University of Pisa

Journals

New England Journal of Medicine

Actions

Institutions

University of Padua

Sapienza University of Rome

Istituti di Ricovero e Cura a Carattere Scientifico

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Also consider